Roche and GE Healthcare are partnering to develop and market an integrated digital diagnostics platform designed to improve oncology and critical care treatment. The platform will apply advanced analytics to in vivo data from GE’s medical imaging and monitoring equipment and to in vitro data from Roche’s biomarker, tissue pathology, genomics, and sequencing portfolio. The platform will then integrate this analysis of testing data with patient records, the results of real-time monitoring, and resources on medical best practices and the latest research outcomes. The aim is to give providers comprehensive decision support using all of these inputs. As an example of how providers might use the platform, oncology care teams that include multiple specialists could review the platform’s data dashboard to collaborate on treatment decisions for cancer patients at each stage of their disease. Roche and GE also hope that the platform will help providers to identify or predict severe complications in critical care settings.
“This is the first time that two major players in healthcare have combined advanced analytics with in vivo and in vitro diagnostics to this degree,” said Kieran Murphy, president and CEO of GE Healthcare. “We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients, and the healthcare industry.”